蔗糖铁注射液治疗血液透析患者肾性贫血的疗效与安全性观察  

The efficacy and safety of intravenous iron sucrose in the treatment of anemia in maintenance hemodialysis patients

作　　者：米绪华[1] 冉建平[2] 张杰[1] 

机构地区：[1]四川大学华西医院肾脏内科,成都610041 [2]重庆市巴南区人民医院泌尿内科,重庆401320

出　　处：《中国血液净化》2009年第2期67-69,共3页Chinese Journal of Blood Purification

摘　　要：目的比较静脉应用蔗糖铁(简称静脉组)与口服多糖铁复合物(简称口服组)治疗使用促红细胞生成素(EPO)的维持性血液透析(MHD)患者肾性贫血的疗效与安全性。方法采用同期随机对照研究。结果治疗后血红蛋白(Hb)、红细胞压积(HCT)、血清铁蛋白(SF)、血清转铁蛋白饱和度(TSAT)两组均有升高,静脉组比口服组升高差异有统计学意义(P<0.05),且上升速度快于口服组;静脉组不良反应少于口服组(P<0.05);治疗前后两组肝功能、C反应蛋白(CRP)等生化指标差异无统计学意义。结论静脉用蔗糖铁治疗MHD患者的肾性贫血安全有效。Objective To determine the efficacy and safety of intravenous iron sucrose （iv group）, and to compare with those of oral polysaccharide iron complex （oral group） in maintenance hemodialysis patients treated with recombinant human erythropoietin. Methods This was a randomized and controlled clinical study. Forty patients were equally divided into the iv group and oral group. Results All the baseline parameters were comparable between the two groups. At the end of the trial, hemoglobin, hemotocrit, serum ferritin and transferrin saturation were significantly increased in both groups. However, the increment of these laboratory parameters was significantly higher in iv group than in oral group （P〈0.05）. There were less adverse effects in iv group than in oral group （P〈0.05）. No differences were found in liver function and serum CRP between the two groups before and after the treatment. Conclusions Intravenous iron sucrose is effective and safe in treating anemic hemodialysis patients

关 键 词：蔗糖铁 肾性贫血 血液透析 

分 类 号：R318.16[医药卫生—生物医学工程]